Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
06 7월 2023 - 8:00PM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, today announced
that three poster presentations will be delivered in-person at the
upcoming Alzheimer’s Association International Conference (AAIC)
2023, to be held July 16 – 20, 2023, virtually and in Amsterdam,
Netherlands. The presentations will highlight data from clinical
and preclinical research of fosgonimeton in Alzheimer’s disease,
and preclinical data of ATH-1105 in models of amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia.
AAIC Presentation Details:
Title: Fosgonimeton, a small-molecule positive
modulator of the HGF/MET system, attenuates amyloid-beta-mediated
toxicity in primary neuron culturesSession: P2-05
Basic Science and Pathogenesis: Molecular and Cell
BiologyPoster Number:
80009Date/Time: Monday, July 17, 2023: 8:45 AM –
4:15 PM CESTPresenter: Sherif Reda, PhD, Associate
Director, Discovery Biology, Athira Pharma
Title: Biomarker analyses from the phase 2,
randomized, placebo-controlled ACT-AD and open-label extension
clinical trials of fosgonimeton in patients with mild-to-moderate
Alzheimer’s diseaseSession: P4-06 Biomarkers:
Biomarkers (non-neuroimaging)Poster Number:
79759Date/Time: Wednesday, July 19, 2023: 8:45 AM
– 4:15 PM CESTPresenter: Hans Moebius, MD, PhD,
Chief Medical Officer, Athira Pharma
Title: ATH-1105, a small-molecule positive
modulator of the HGF/MET system, is neuroprotective and attenuates
TDP-43 protein pathology in ALS and frontotemporal
dementia-relevant preclinical models Session:
P4-05 Basic Science and Pathogenesis: Molecular and Cell
BiologyPoster Number:
80041Date/Time: Wednesday, July 19, 2023: 8:45 AM
– 4:15 PM CESTPresenter: Jewel Johnston, PhD,
Director, In Vivo Pharmacology, Athira Pharma
Full abstracts will be available to registered AAIC attendees.
Access more information about AAIC 2023 here.
About Athira Pharma, Inc.Athira Pharma, Inc.,
headquartered in the Seattle, Washington area, is a late
clinical-stage biopharmaceutical company focused on developing
small molecules to restore neuronal health and slow
neurodegeneration. Athira aims to alter the course of neurological
diseases by advancing its pipeline of therapeutic candidates
targeting the HGF/MET neurotrophic system for Alzheimer’s and
Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic
lateral sclerosis (ALS). For more information, visit
www.athira.com. You can also follow Athira on
Facebook, LinkedIn and @athirapharma on Twitter and
Instagram.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding: product
candidates as a potential treatment for Alzheimer’s disease,
Parkinson’s disease, Dementia with Lewy bodies, and other
neurodegenerative diseases, such as amyotrophic lateral sclerosis;
Athira’s platform technology and potential therapies; future
development plans; expectations regarding the potential efficacy
and commercial potential of Athira’s product candidates; and
Athira’s ability to advance its product candidates into later
stages of development. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as “may,”
“will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,”
“intend,” “pursue,” “continue,” “suggest,” “potential,” and other
similar expressions, among others. Any forward-looking statements
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, the data for our
product candidates from our preclinical and clinical trials not
supporting the safety, efficacy and tolerability of our product
candidates; cessation or delay of Athira’s development of product
candidates may occur; regulatory authorities could object to
protocols, amendments and other submissions; future potential
regulatory milestones for product candidates, including those
related to current and planned clinical studies, may be
insufficient to support regulatory submissions or approval; the
impact of the COVID-19 pandemic on Athira’s business, research and
clinical development plans and timelines, and the regulatory
process for Athira product candidates; Athira may not be able to
recruit sufficient patients for its clinical trials; the outcome of
legal proceedings that have been or may in the future be instituted
against us and certain of our directors and officers; clinical
trials may not demonstrate safety and efficacy of any of Athira’s
product candidates; possible negative interactions of Athira's
product candidates with other treatments; Athira’s assumptions
regarding the sufficiency of its cash, cash equivalents and
investments to fund its planned operations may be incorrect;
adverse conditions in the general domestic and global economic
markets; the impact of competition; regulatory agencies may be
delayed in reviewing, commenting on or approving any of Athira’s
clinical development plans as a result of the COVID-19 pandemic,
which could further delay development timelines; the impact of
expanded product development and clinical activities on operating
expenses; the impact of new or changing laws and regulations; as
well as the other risks detailed in Athira’s filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and Athira undertakes
no obligation to update forward-looking statements. Athira may not
actually achieve the plans, intentions, or expectations disclosed
in its forward-looking statements, and you should not place undue
reliance on the forward-looking statements.
Investor & Media ContactJulie RathbunAthira
PharmaJulie.rathbun@athira.com 206-769-9219
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024